Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte PD-L1 Assay

RareCyte has launched its PD-L1 liquid biopsy assay, which the firm said will allow users to evaluate PD-L1 expression on circulating tumor cells in a patient's bloodstream. Customers can use the PD-L1 assay and the AccuCyte-CyteFinder system to process blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, or process blood to plasma for optional cell-free DNA analysis.